Aquinox provides enrollment update for LEADERSHIP 301 clinical trial of rosiptor
Aquinox announced it has met its enrollment threshold of 300 females in its LEADERSHIP 301 clinical trial of rosiptor (AQX-1125) in interstitial cystitis/bladder pain syndrome and remains on track for topline data in the third quarter of 2018. February 09, 2018